Is Revvity (RVTY) Fairly Valued Following Its Anthropic Signals AI Tie Up?
Revvity (RVTY) is back in focus after announcing that its Revvity Signals Software business has joined Anthropic's Model Context Protocol connector directory, linking Signals AI with Claude and Claude Science for scientific research workflows.
See our latest analysis for Revvity.
Revvity's latest AI partnership lands as the stock trades at US$111.11, with a 30 day share price return of 11.49% and 90 day share price return of 18.82%. The 1 year total shareholder return of 13.16% contrasts with weaker 3 and 5 year total shareholder returns.
If this kind of AI driven story has your attention, it could be a good moment to broaden your watchlist with 40 healthcare AI stocks
Revvity has rallied on the Anthropic tie up and still trades below some fair value estimates and analyst targets. Is that discount a genuine opportunity, or a signal that the market wants more proof before it re rates the stock?
Most Popular Narrative: 2.2% Undervalued
The most followed narrative currently pegs Revvity's fair value at $113.64, only slightly above the last close at $111.11. This sets up a finely balanced valuation story.
Ongoing shift in product mix toward higher margin, software enabled and consumables driven offerings (e.g., SaaS Signals, reagents, new IDS i20 platform), along with structural cost actions, are expected to materially expand operating and net margins, with 2026 set to start at a higher 28% operating margin baseline.
Want to see what kind of revenue profile and margin rebuild sits behind that mix shift story? The narrative leans on measured growth, rising profitability and a richer earnings multiple to get to its fair value anchor.
Result: Fair Value of $113.64 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, investors still need to factor in risks around regulatory pressure in key diagnostics markets and softer academic or government demand, which could challenge the Revvity narrative.
Find out about the key risks to this Revvity narrative.
Next Steps
With both concerns and optimism around Revvity already on the table, this is a good moment to move quickly and conduct your own stress test of the balance of risks and rewards using the 2 key rewards and 1 important warning sign
Looking for more investment ideas beyond Revvity?
If Revvity has sharpened your focus, do not stop there. Broaden your opportunity set with a few targeted stock ideas built from the Simply Wall Street Screener.
- Spot potential value candidates early by scanning 46 high quality undervalued stocks that pair quality fundamentals with pricing that may look appealing.
- Strengthen your income watchlist by reviewing 8 dividend fortresses that offer higher yields alongside an emphasis on resilience.
- Prioritize capital protection by filtering for 80 resilient stocks with low risk scores so you are not overlooking stocks with more measured risk profiles.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com